Patents by Inventor Brent Hanks

Brent Hanks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TUMOR-INTRINSIC NLRP3 INFLAMMASOME SIGNALING PATHWAY AS A GENETIC AND FUNCTIONAL BIOMARKER FOR IMMUNOTHERAPY RESPONSE
    Publication number: 20230152324
    Abstract: The present disclosure describes methods and markers in the NLRP3-HSP70 axis useful for making treatment decisions regarding cancer.
    Type: Application
    Filed: November 14, 2022
    Publication date: May 18, 2023
    Inventors: Brent A. Hanks, Balamayooran Theivanthiran
  • Predictive biomarkers for cancer immunotherapy and methods of using same
    Patent number: 11643691
    Abstract: The present disclosure provides methods of detecting a wnt-?-catenin-mediated cancer and an immunotherapy resistant cancer by detecting the presence of an associated biomarker. Further, methods of threating the wnt-?-catenin-mediated cancer or immunotherapy resistant cancer are provided.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: May 9, 2023
    Assignee: Duke University
    Inventors: Brent Hanks, Nicholas Devito, Balamayooran Theivanthiran, Fei Zhao
  • INDUCED ACTIVATION IN DENDRITIC CELLS
    Publication number: 20220233670
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Application
    Filed: September 17, 2021
    Publication date: July 28, 2022
    Inventors: David Spencer, Brent Hanks, Kevin Slawin
  • COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF ANTI-PD-1 ANTIBODY IMMUNOTHERAPY
    Publication number: 20210077582
    Abstract: The present disclosure provides, in part, compositions and methods of increasing the efficacy of anti-PD-1/PD-L1 antibody immunotherapy in a subject. The compositions and methods comprise an NLRP3 inhibitor used in combination with a PD-1 or PD-L1 inhibitor for the treatment of cancer.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 18, 2021
    Applicant: Duke University
    Inventors: Brent Hanks, Balamayooran Theivanthiran
  • INDUCED ACTIVATION IN DENDRITIC CELLS
    Publication number: 20200197502
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Application
    Filed: August 6, 2019
    Publication date: June 25, 2020
    Inventors: David Spencer, Brent Hanks, Kevin Slawin
  • Composition of matter and methods for alteration of dendritic cell metabolism to augment cancer vaccine efficacy
    Patent number: 10617749
    Abstract: This disclosure provides compositions of matter and methods for alteration of dendritic cell metabolism to augment cancer vaccine efficacy. The compositions and methods can involve regulation of fatty acid oxidation.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: April 14, 2020
    Assignee: Duke University
    Inventors: Brent Hanks, Fei Zhao
  • PREDICTIVE BIOMARKERS FOR CANCER IMMUNOTHERAPY AND METHODS OF USING SAME
    Publication number: 20190316208
    Abstract: The present disclosure provides methods of detecting a wnt-?-catenin-mediated cancer and an immunotherapy resistant cancer by detecting the presence of an associated biomarker. Further, methods of threating the wnt-?-catenin-mediated cancer or immunotherapy resistant cancer are provided.
    Type: Application
    Filed: April 15, 2019
    Publication date: October 17, 2019
    Inventors: Brent Hanks, Nicholas Devito, Balamayooran Theivanthiran, Fei Zhao
  • Induced activation in dendritic cells
    Patent number: 10420824
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: September 24, 2019
    Assignee: Baylor College of Medicine
    Inventors: David Spencer, Brent Hanks, Kevin Slawin
  • INDUCED ACTIVATION IN DENDRITIC CELLS
    Publication number: 20170182140
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Application
    Filed: January 5, 2017
    Publication date: June 29, 2017
    Inventors: David SPENCER, Brent HANKS, Kevin SLAWIN
  • Induced activation in dendritic cells
    Patent number: 9572835
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: February 21, 2017
    Assignee: BAYLOR COLLEGE OF MEDICINE
    Inventors: David Spencer, Brent Hanks, Kevin Slawin
  • INDUCED ACTIVATION IN DENDRITIC CELLS
    Publication number: 20150306140
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Application
    Filed: March 10, 2015
    Publication date: October 29, 2015
    Inventors: David SPENCER, Brent HANKS, Kevin SLAWIN
  • Induced activation in dendritic cells
    Patent number: 8999949
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: April 7, 2015
    Assignee: Baylor College of Medicine
    Inventors: David Spencer, Brent Hanks, Kevin Slawin
  • Induced activation in dendritic cells
    Patent number: 8771671
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: July 8, 2014
    Assignee: Baylor College of Medicine
    Inventors: David Spencer, Brent Hanks, Kevin Slawin
  • INDUCED ACTIVATION IN DENDRITIC CELLS
    Publication number: 20080269160
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Application
    Filed: June 30, 2008
    Publication date: October 30, 2008
    Inventors: David Spencer, Brent Hanks, Kevin Slawin
  • Induced activation in dendritic cell
    Patent number: 7404950
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Grant
    Filed: February 18, 2004
    Date of Patent: July 29, 2008
    Assignee: Baylor College of Medicine
    Inventors: David Spencer, Brent Hanks, Kevin Slawin
  • Induced activation in dendritic cell
    Publication number: 20040209836
    Abstract: The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.
    Type: Application
    Filed: February 18, 2004
    Publication date: October 21, 2004
    Inventors: David Spencer, Brent Hanks, Kevin Slawin